卵巢癌腹腔内顺铂治疗：与标准静脉注射卡铂和紫杉醇的比较。 - Suppr

Suppr

超能文献

Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.

作者信息

Ozols Robert F, Bookman Michael A, du Bois Andreas, Pfisterer Jacobus, Reuss Alexander, Young Robert C

出版信息

Gynecol Oncol. 2006 Oct;103(1):1-6. doi: 10.1016/j.ygyno.2006.06.026. Epub 2006 Aug 10.

DOI:10.1016/j.ygyno.2006.06.026

PMID:16904166

Abstract

摘要

相似文献

Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.卵巢癌腹腔内顺铂治疗：与标准静脉注射卡铂和紫杉醇的比较。

Gynecol Oncol. 2006 Oct;103(1):1-6. doi: 10.1016/j.ygyno.2006.06.026. Epub 2006 Aug 10.

Intraperitoneal therapy for ovarian cancer: why has it not become standard?卵巢癌的腹腔内治疗：为何尚未成为标准治疗方法？

J Natl Cancer Inst. 2009 Jun 3;101(11):775-7. doi: 10.1093/jnci/djp151. Epub 2009 May 26.

Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.顺铂和紫杉醇腹腔内注射与卡铂和紫杉醇静脉注射治疗Ⅲ期卵巢癌的疗效对比：成本效益分析

Gynecol Oncol. 2007 Sep;106(3):476-81. doi: 10.1016/j.ygyno.2007.05.043. Epub 2007 Aug 3.

Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment.卵巢癌的腹腔内化疗：综述，重点关注治疗的实际方面。

J Clin Oncol. 2006 Feb 20;24(6):988-94. doi: 10.1200/JCO.2005.05.2456. Epub 2006 Feb 6.

Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?在晚期卵巢癌中，腹腔内化疗应被视为标准的一线治疗方法吗？

Crit Rev Oncol Hematol. 2007 May;62(2):137-47. doi: 10.1016/j.critrevonc.2006.11.009. Epub 2006 Dec 26.

Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.妇科肿瘤学 Arbeitsgemeinschaft 卵巢癌研究组的随机研究：比较顺铂/紫杉醇与卡铂/紫杉醇治疗的卵巢癌患者的生活质量。

J Clin Oncol. 2006 Feb 1;24(4):579-86. doi: 10.1200/JCO.2005.02.4067.

The feasibility of carboplatin-based intraperitoneal chemotherapy in ovarian cancer.顺铂腹腔化疗治疗卵巢癌的可行性。

Eur J Obstet Gynecol Reprod Biol. 2010 Oct;152(2):195-9. doi: 10.1016/j.ejogrb.2010.05.033. Epub 2010 Jun 23.

Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis.

Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-36-S15-39.

Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.紫杉醇（泰素）/卡铂联合化疗治疗晚期卵巢癌

Semin Oncol. 2000 Jun;27(3 Suppl 7):3-7.

Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.在III期卵巢癌和原发性腹膜癌最佳分期患者中静脉化疗与腹腔化疗对比试验的腹腔导管结局：一项妇科肿瘤学组研究

Gynecol Oncol. 2006 Jan;100(1):27-32. doi: 10.1016/j.ygyno.2005.11.013.

引用本文的文献

Cisplatin induces BDNF downregulation in middle-aged female rat model while BDNF enhancement attenuates cisplatin neurotoxicity.顺铂诱导中年雌性大鼠模型中 BDNF 的下调，而 BDNF 的增强可减轻顺铂的神经毒性。

Exp Neurol. 2024 May;375:114717. doi: 10.1016/j.expneurol.2024.114717. Epub 2024 Feb 8.

Novel Nanocomplexes Targeting STAT3 Demonstrate Promising Anti-Ovarian Cancer Effects in vivo.靶向信号转导和转录激活因子3的新型纳米复合物在体内显示出有前景的抗卵巢癌作用。

Onco Targets Ther. 2020 Jun 8;13:5069-5082. doi: 10.2147/OTT.S247398. eCollection 2020.

MicroRNA-32 promotes ovarian cancer cell proliferation and motility by targeting SMG1.微小RNA-32通过靶向SMG1促进卵巢癌细胞增殖和运动。

Oncol Lett. 2020 Jul;20(1):733-741. doi: 10.3892/ol.2020.11624. Epub 2020 May 14.

Silenced PITX1 promotes chemotherapeutic resistance to 5-fluorocytosine and cisplatin in gastric cancer cells.沉默的PITX1促进胃癌细胞对5-氟胞嘧啶和顺铂的化疗耐药性。

Exp Ther Med. 2019 May;17(5):4046-4054. doi: 10.3892/etm.2019.7459. Epub 2019 Apr 1.

First-line and maintenance therapy for ovarian cancer: current status and future directions.卵巢癌的一线和维持治疗：现状与未来方向。

Drugs. 2014 Jun;74(8):879-89. doi: 10.1007/s40265-014-0221-9.

Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study.在接受紫杉醇联合顺铂治疗的上皮性卵巢癌患者中，异甘草酸镁增加紫杉醇的清除率：一项初步临床研究。

Eur J Drug Metab Pharmacokinet. 2014 Mar;39(1):25-31. doi: 10.1007/s13318-013-0136-y. Epub 2013 May 17.

Inhibition of EGFR-AKT axis results in the suppression of ovarian tumors in vitro and in preclinical mouse model.抑制 EGFR-AKT 轴可抑制体外卵巢肿瘤和临床前小鼠模型中的肿瘤生长。

PLoS One. 2012;7(8):e43577. doi: 10.1371/journal.pone.0043577. Epub 2012 Aug 27.

Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents.卵巢癌：一线治疗策略的进展，特别关注抗血管生成药物。

Curr Oncol Rep. 2012 Dec;14(6):509-18. doi: 10.1007/s11912-012-0274-4.

Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3).二吲哚甲烷通过靶向信号转导子和转录激活子 3（STAT3）抑制卵巢癌细胞生长，并增强顺铂在肿瘤小鼠模型中的疗效。

BMC Med. 2012 Jan 26;10:9. doi: 10.1186/1741-7015-10-9.

Blocking epidermal growth factor receptor activation by 3,3'-diindolylmethane suppresses ovarian tumor growth in vitro and in vivo.3,3'-二吲哚甲烷通过阻断表皮生长因子受体的激活来抑制卵巢肿瘤在体外和体内的生长。

J Pharmacol Exp Ther. 2012 Apr;341(1):24-32. doi: 10.1124/jpet.111.188706. Epub 2011 Dec 28.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验